KMT2A::CBL,

Jinglei Yu1,2,3,4, Fengmei Song1,2,3,4, Mingming Zhang1,2,3,4

  • 1Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

PubMed
概括

在急性白血病中罕见的KMT2A::CBL基因融合导致预后不佳和治疗耐药性. 这项研究详细介绍了一个案例,并回顾了类似的实例,为白血病发生提供了洞察力.